Abstract
The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Keywords: HLA class I, cancer, immune escape
Current Cancer Therapy Reviews
Title: HLA Class I Expression, Tumor Escape and Cancer Progression
Volume: 4 Issue: 2
Author(s): Natalia Aptsiauri, Teresa Cabrera, Angel Garcia Lora, Francisco Ruiz-Cabello and Federico Garrido
Affiliation:
Keywords: HLA class I, cancer, immune escape
Abstract: The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Export Options
About this article
Cite this article as:
Aptsiauri Natalia, Cabrera Teresa, Lora Garcia Angel, Ruiz-Cabello Francisco and Garrido Federico, HLA Class I Expression, Tumor Escape and Cancer Progression, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310052
DOI https://dx.doi.org/10.2174/157339408784310052 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemistry in the Bioactivity of Chlorophylls: An Overview
Current Medicinal Chemistry Experimental and Computational Insights into Bis-indolylmethane Derivatives as Potent Antimicrobial Agents Inhibiting 2,2-dialkylglycine Decarboxylase
Current Enzyme Inhibition Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma
Current Topics in Medicinal Chemistry Medication Conveyance Through Nose: Factors Affecting and Novel Applications
Drug Delivery Letters Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers Ethnomedicinal Uses, Phytochemistry and Pharmacology of Carica papaya Plant: A Compendious Review
Mini-Reviews in Organic Chemistry 4'-Thionucleosides as Potent and Selective A<sub>3</sub> Adenosine Receptor Ligands
Current Organic Chemistry Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds The Endocannabinoid System and Pain
CNS & Neurological Disorders - Drug Targets Current and Potential Use of Citrus Essential Oils
Current Organic Chemistry Carbohydrate Antigens: Synthesis Aspects and Immunological Applications in Cancer
Mini-Reviews in Medicinal Chemistry Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Therapeutic Targeting of G-Protein Coupled Receptor-Mediated Epidermal Growth Factor Receptor Transactivation in Human Glioma Brain Tumors
Mini-Reviews in Medicinal Chemistry Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics